Communiqués Xintela AB

Actions

XINT

SE0007756903

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 21/09/2026			Varia. 5j.	Varia. 1 janv.
0,1575 ^SEK	-2,17%		-1,56%	-44,54%

28/08	Xintela AB (publ) publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
01/06	Xintela, participation de Flerie, publie des résultats cliniques positifs pour son produit de thérapie cellulaire	FW

Communiqués

03/09	Xintela: Exploring paths for XSTEM OA	AQ
28/08	Xintela : Interim Report January – June 2026	PU
28/08	Xintela AB Interim Report January - June 2026	AQ
11/08	Xintela publishes safety and efficacy results from knee osteoarthritis clinical study with XSTEM in scientific journal	AQ
04/06	Xintela: Completing another phase I/IIa study	AQ
01/06	Flerie’s portfolio company Xintela presents positive results from clinical study with its stem cell product XSTEM	AQ
29/05	Xintela AB Interim Report January - March 2026	AQ
29/05	Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers	AQ
28/05	Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB	AQ
12/05	Xintela : Maj 12, 2026	PU
12/05	Xintela granted patent in Japan for XSTEM® treatment of acute respiratory distress syndrome (ARDS)	AQ
30/04	Xintela AB publishes Annual Report 2025	AQ
14/04	Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects	AQ
13/04	Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper	AQ
03/03	Xintela: Moving forward with XSTEM	AQ
27/02	Xintela AB Year-end Report 2025	AQ
20/02	Xintela : New issue of Xintelling No. 1 2026	PU
17/02	Professor Hall comments on Xintela's study results	AQ
13/02	Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers	AQ
12/12	Xintela: Extending the financial runway	AQ
12/11	Xintela: Focus on study results and financing	AQ
04/11	Xintela AB Interim Report January - September 2025	AQ
30/10/25	Last patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers	AQ
07/10/25	Xintela announces subsidiary Targinta collaboration with MSK Therapeutics Accelerator	AQ
23/09/25	Flerie's portfolio company Xintela has presented positive 24-month data for its stem cell product XSTEM	AQ